ACURA PHARMACEUTICALS, INC: debt financing — Acura extends loan maturity and NDA deadline to May 31; warns of possible shutdown without new financing

ACURA PHARMACEUTICALS, INC

Received $325k in new loans from AD Pharma in Feb 2025; total principal $7.49M at 5.25% interest.
Maturity of secured note and warrant expiration extended from Feb 28 to May 31, 2025.
LTX-03 NDA acceptance deadline extended to May 31, 2025; AD Pharma may terminate and take IP if not accepted.
Without additional financing by mid-March 2025, company will scale back operations, furlough employees, or terminate operations.
AD Pharma (controlled by John Schutte) owns ~65% of Acura's outstanding common stock.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ACURA PHARMACEUTICALS, INC incurred loan of loans of $100,000, $100,000 and $125,000 with Abuse Deterrent Pharma, LLC at 5.25%.

Instrument: loan
Principal: loans of $100,000, $100,000 and $125,000
Counterparty: Abuse Deterrent Pharma, LLC
Rate: 5.25%
Event: incurrence

Exact text from the filing

On both February 28, 2025, February 14, 2025, and February 3, 2025, we received loans of $100,000, $100,000 and $125,000, respectively from Abuse Deterrent Pharma, LLC (“AD Pharma”).

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ACURA PHARMACEUTICALS, INC amended loan with Abuse Deterrent Pharma, LLC maturing May 31, 2025.

Instrument: loan
Counterparty: Abuse Deterrent Pharma, LLC
Maturity: May 31, 2025
Event: amendment

Exact text from the filing

This amendment #5 has an effective date of February 28, 2025 and changes the maturity date of the Amended Note from February 28, 2025 to May 31, 2025, at which time all principal and interest is due.

View on SEC.gov

Browse all debt financings →

Source: SEC EDGAR

accession 0001104659-25-020108

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.